首页> 外文期刊>Transplant immunology >iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers in serum of acute cellular rejection after liver transplantation
【24h】

iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers in serum of acute cellular rejection after liver transplantation

机译:基于ITRAQ的定量蛋白质组学分析显示肝移植后急性细胞排斥血清中的潜在早期诊断标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Liver transplantation (LT) is the most effective treatment method for advanced stage liver disease but acute cellular rejection (ACR) seriously affects the prognosis of LT. To discover novel diagnostic biomarkers of ACR after LT, Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-based mass spectrometry was performed to characterize alterations of serum proteins among patients validated to be pathologically ACR or pathologically no-ACR after LT and healthy controls. As a result, 10 differentially expressed proteins were found out between the ACR group and the No-ACR group; 88 differentially expressed proteins were found out between the ACR group and the Healthy Control group; 39 differentially expressed proteins were found out between No-ACR group and Healthy Control group. After analysis and ELISA validation, the results showed that CFHR1, CFHR5 and CFH could be candidate protein biomarkers for the early diagnosis of ACR after LT.
机译:肝移植(LT)是前期肝病最有效的治疗方法,但急性细胞排斥(ACR)严重影响了LT的预后。 为了在LT的情况下探讨ACR的新型诊断生物标志物,进行相对和绝对定量(ITRAQ)的异质标签,以表征验证患者血清蛋白的改变,验证的患者是病理上的ACR或病理上NO-ACR后的治疗患者。 结果,ACR组和NO-ACR组之间发现了10种差异表达的蛋白质; 在ACR组和健康对照组之间发现了差异表达的蛋白质; 在NO-ACR组和健康对照组之间发现了39种差异表达的蛋白质。 在分析和ELISA验证后,结果表明CFHR1,CFHR5和CFH可以是候选蛋白生物标志物,以便在LT后的ACR早期诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号